Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274709 | 0.85 | GAA (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13884554 | 0.82 | ALDH1A1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL12284783 | 0.80 | ALDH1A1 (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4904207 | 0.77 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL9577787 | 0.77 | GAA (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Methane SCHEMBL4902707 | 0.75 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL12017279 | 0.74 | ALDH1A1 (0.38) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL14079942 | 0.74 | GAA (0.36) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL14079889 | 0.74 | ALDH1A1 (0.36) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL27298747 | 0.72 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2489656-A1 | Selective androgen receptor modulators (sarms) and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012041862-A1 | APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| US-8022085-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2011043387-A1 | PYRAZOLOXAZOLE COMPOUND | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| WO-2009082437-A9 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010030967-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009146034-A2 | MAPK/ERK KINASE INHIBITORS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008136948-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137176-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008127274-A2 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | MAPK1, MAP4K2, MAP3K1 | MGAM 4882/4885GAA 4729/4885SI 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.